ABL1 Q252H Recombinant Human Active Protein Kinase
The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML) . ABL1 Q252H Recombinant Human Active Protein Kinase is a recombinant ABL1 Q252H protein that can be used to study ABL1 Q252H-related functions[1].
Product Specifications
UNSPSC
12352211
Target
Bcr-Abl
Related Pathways
Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
[ABL1Q252HRecombinantHumanActiveProteinKinase]
References & Citations
[1]Yusoff YM, et al. Identification of novel BCR::ABL1 kinase domain mutation in patients with chronic myeloid leukaemia and imatinib resistance. Malays J Pathol. 2024 Dec;46 (3) :431-439.
Shipping Conditions
Room temperature
Scientific Category
Enzyme
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
143672-FITC 100 µL
SCF (Kit Ligand, C-kit Ligand, Stem Cell Factor, Mast Cell Growth Factor, MGF, KITLG, DKFZp686F2250) (FITC)
Ask
View Details 141680 200 µL
Nitric Oxide Synthase 3, Endothelial (NOS3, ECNOS, NOS III, E-NOS, C-NOS, ENOS, CNOS, Constitutive NOS)
Ask
View Details